Homocysteine and cardiovascular disease : cause or effect?

Both markedly and mildly elevated circulating homocysteine concentrations are associated with increased risk of vascular occlusion. Here we review possible mechanisms that mediate these effects. Inborn errors of homocysteine metabolism result in markedly elevated plasma homocysteine (200-300 micromo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The American journal of clinical nutrition 2000-08, Vol.72 (2), p.315-323
Hauptverfasser: BRATTSTRÖM, L, EL WILCKEN, D
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 323
container_issue 2
container_start_page 315
container_title The American journal of clinical nutrition
container_volume 72
creator BRATTSTRÖM, L
EL WILCKEN, D
description Both markedly and mildly elevated circulating homocysteine concentrations are associated with increased risk of vascular occlusion. Here we review possible mechanisms that mediate these effects. Inborn errors of homocysteine metabolism result in markedly elevated plasma homocysteine (200-300 micromol/L) and thromboembolic (mainly venous) disease: treatment to lower but not to normalize these concentrations prevents vascular events. Mild homocysteine elevation (>15 micromol/L) occurs in approximately 20-30% of patients with atherosclerotic disease. Usually, this is easily normalized with oral folate and ongoing trials are assessing the effect of folate treatment on outcomes. Although there is evidence of endothelial dysfunction with both markedly and mildly elevated homocysteine concentrations, the elevated homocysteine concentration in atherosclerotic patients is also associated with most standard vascular risk factors, and importantly, with early decline in renal function, which is common in atherosclerosis. Decline in renal function alone causes elevated plasma homocysteine (and cysteine). These observations suggest that mild hyperhomocysteinemia could often be an effect rather than a cause of atherosclerotic disease. Data on the common C677T methylenetetrahydrofolate reductase polymorphism supports this, in that, although homozygosity is a frequent cause of mild hyperhomocysteinemia when plasma folate is below median population concentrations, it appears not to increase cardiovascular risk. Indeed, there is recent evidence suggesting an acute antioxidant effect of folic acid independent of its effect on homocysteine concentrations. This antioxidant mechanism may oppose an oxidant effect of homocysteine and be relevant to treatment of patients with vascular disease, especially those with chronic renal insufficiency. Such patients have moderately elevated plasma homocysteine and greatly increased cardiovascular risk that is largely unexplained.
doi_str_mv 10.1093/ajcn/72.2.315
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71244845</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>57795187</sourcerecordid><originalsourceid>FETCH-LOGICAL-c450t-88b4f93d8c7f0a70bc8b71328be2d033e80b41a97d8905637005b8cab2830ffa3</originalsourceid><addsrcrecordid>eNpd0E1LwzAYwPEgipvTo1cpIt66PXlpk3gRGeqEgRc9hyRNoKMvM2mFfXszNlA8PYf88pD8EbrGMMcg6UJvbLfgZE7mFBcnaIolFTklwE_RFABILnFZTNBFjBsATJgoz9Ek3cRSEpiih1Xf9nYXB1d3LtNdlVkdqrr_1tGOjQ5ZVUeno8se0sGYZh8y572zw-MlOvO6ie7qOGfo8-X5Y7nK1--vb8undW5ZAUMuhGFe0kpY7kFzMFYYjikRxpEKKHUCDMNa8kpIKErKAQojrDZEUPBe0xm6P-zdhv5rdHFQbR2taxrduX6MiqdfMcGKBG__wU0_hi69TRGKJeFU4ITyA7KhjzE4r7ahbnXYKQxqX1TtiypOFFGpaPI3x6WjaV31Rx8SJnB3BCmZbnzQna3jr2OclJTRH-iAfIw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>231927381</pqid></control><display><type>article</type><title>Homocysteine and cardiovascular disease : cause or effect?</title><source>MEDLINE</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>BRATTSTRÖM, L ; EL WILCKEN, D</creator><creatorcontrib>BRATTSTRÖM, L ; EL WILCKEN, D</creatorcontrib><description>Both markedly and mildly elevated circulating homocysteine concentrations are associated with increased risk of vascular occlusion. Here we review possible mechanisms that mediate these effects. Inborn errors of homocysteine metabolism result in markedly elevated plasma homocysteine (200-300 micromol/L) and thromboembolic (mainly venous) disease: treatment to lower but not to normalize these concentrations prevents vascular events. Mild homocysteine elevation (&gt;15 micromol/L) occurs in approximately 20-30% of patients with atherosclerotic disease. Usually, this is easily normalized with oral folate and ongoing trials are assessing the effect of folate treatment on outcomes. Although there is evidence of endothelial dysfunction with both markedly and mildly elevated homocysteine concentrations, the elevated homocysteine concentration in atherosclerotic patients is also associated with most standard vascular risk factors, and importantly, with early decline in renal function, which is common in atherosclerosis. Decline in renal function alone causes elevated plasma homocysteine (and cysteine). These observations suggest that mild hyperhomocysteinemia could often be an effect rather than a cause of atherosclerotic disease. Data on the common C677T methylenetetrahydrofolate reductase polymorphism supports this, in that, although homozygosity is a frequent cause of mild hyperhomocysteinemia when plasma folate is below median population concentrations, it appears not to increase cardiovascular risk. Indeed, there is recent evidence suggesting an acute antioxidant effect of folic acid independent of its effect on homocysteine concentrations. This antioxidant mechanism may oppose an oxidant effect of homocysteine and be relevant to treatment of patients with vascular disease, especially those with chronic renal insufficiency. Such patients have moderately elevated plasma homocysteine and greatly increased cardiovascular risk that is largely unexplained.</description><identifier>ISSN: 0002-9165</identifier><identifier>EISSN: 1938-3207</identifier><identifier>DOI: 10.1093/ajcn/72.2.315</identifier><identifier>PMID: 10919920</identifier><identifier>CODEN: AJCNAC</identifier><language>eng</language><publisher>Bethesda, MD: American Society for Clinical Nutrition</publisher><subject>Amino acids ; Aminoacid disorders ; Biological and medical sciences ; Blood and lymphatic vessels ; Cardiology. Vascular system ; Cardiovascular disease ; Cardiovascular Diseases - etiology ; Cardiovascular Diseases - prevention &amp; control ; Dietary Supplements ; Enzymes ; Errors of metabolism ; Folic Acid - administration &amp; dosage ; Homocysteine - blood ; Homocystinuria - complications ; Humans ; Hyperhomocysteinemia - physiopathology ; Kidney - physiopathology ; Kidney Diseases - physiopathology ; Medical research ; Medical sciences ; Metabolic diseases ; Miscellaneous ; Oxidation ; Vitamin B</subject><ispartof>The American journal of clinical nutrition, 2000-08, Vol.72 (2), p.315-323</ispartof><rights>2000 INIST-CNRS</rights><rights>Copyright American Society for Clinical Nutrition, Inc. Aug 2000</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c450t-88b4f93d8c7f0a70bc8b71328be2d033e80b41a97d8905637005b8cab2830ffa3</citedby><cites>FETCH-LOGICAL-c450t-88b4f93d8c7f0a70bc8b71328be2d033e80b41a97d8905637005b8cab2830ffa3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=1472634$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10919920$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>BRATTSTRÖM, L</creatorcontrib><creatorcontrib>EL WILCKEN, D</creatorcontrib><title>Homocysteine and cardiovascular disease : cause or effect?</title><title>The American journal of clinical nutrition</title><addtitle>Am J Clin Nutr</addtitle><description>Both markedly and mildly elevated circulating homocysteine concentrations are associated with increased risk of vascular occlusion. Here we review possible mechanisms that mediate these effects. Inborn errors of homocysteine metabolism result in markedly elevated plasma homocysteine (200-300 micromol/L) and thromboembolic (mainly venous) disease: treatment to lower but not to normalize these concentrations prevents vascular events. Mild homocysteine elevation (&gt;15 micromol/L) occurs in approximately 20-30% of patients with atherosclerotic disease. Usually, this is easily normalized with oral folate and ongoing trials are assessing the effect of folate treatment on outcomes. Although there is evidence of endothelial dysfunction with both markedly and mildly elevated homocysteine concentrations, the elevated homocysteine concentration in atherosclerotic patients is also associated with most standard vascular risk factors, and importantly, with early decline in renal function, which is common in atherosclerosis. Decline in renal function alone causes elevated plasma homocysteine (and cysteine). These observations suggest that mild hyperhomocysteinemia could often be an effect rather than a cause of atherosclerotic disease. Data on the common C677T methylenetetrahydrofolate reductase polymorphism supports this, in that, although homozygosity is a frequent cause of mild hyperhomocysteinemia when plasma folate is below median population concentrations, it appears not to increase cardiovascular risk. Indeed, there is recent evidence suggesting an acute antioxidant effect of folic acid independent of its effect on homocysteine concentrations. This antioxidant mechanism may oppose an oxidant effect of homocysteine and be relevant to treatment of patients with vascular disease, especially those with chronic renal insufficiency. Such patients have moderately elevated plasma homocysteine and greatly increased cardiovascular risk that is largely unexplained.</description><subject>Amino acids</subject><subject>Aminoacid disorders</subject><subject>Biological and medical sciences</subject><subject>Blood and lymphatic vessels</subject><subject>Cardiology. Vascular system</subject><subject>Cardiovascular disease</subject><subject>Cardiovascular Diseases - etiology</subject><subject>Cardiovascular Diseases - prevention &amp; control</subject><subject>Dietary Supplements</subject><subject>Enzymes</subject><subject>Errors of metabolism</subject><subject>Folic Acid - administration &amp; dosage</subject><subject>Homocysteine - blood</subject><subject>Homocystinuria - complications</subject><subject>Humans</subject><subject>Hyperhomocysteinemia - physiopathology</subject><subject>Kidney - physiopathology</subject><subject>Kidney Diseases - physiopathology</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Metabolic diseases</subject><subject>Miscellaneous</subject><subject>Oxidation</subject><subject>Vitamin B</subject><issn>0002-9165</issn><issn>1938-3207</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2000</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpd0E1LwzAYwPEgipvTo1cpIt66PXlpk3gRGeqEgRc9hyRNoKMvM2mFfXszNlA8PYf88pD8EbrGMMcg6UJvbLfgZE7mFBcnaIolFTklwE_RFABILnFZTNBFjBsATJgoz9Ek3cRSEpiih1Xf9nYXB1d3LtNdlVkdqrr_1tGOjQ5ZVUeno8se0sGYZh8y572zw-MlOvO6ie7qOGfo8-X5Y7nK1--vb8undW5ZAUMuhGFe0kpY7kFzMFYYjikRxpEKKHUCDMNa8kpIKErKAQojrDZEUPBe0xm6P-zdhv5rdHFQbR2taxrduX6MiqdfMcGKBG__wU0_hi69TRGKJeFU4ITyA7KhjzE4r7ahbnXYKQxqX1TtiypOFFGpaPI3x6WjaV31Rx8SJnB3BCmZbnzQna3jr2OclJTRH-iAfIw</recordid><startdate>20000801</startdate><enddate>20000801</enddate><creator>BRATTSTRÖM, L</creator><creator>EL WILCKEN, D</creator><general>American Society for Clinical Nutrition</general><general>American Society for Clinical Nutrition, Inc</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T7</scope><scope>7TS</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>20000801</creationdate><title>Homocysteine and cardiovascular disease : cause or effect?</title><author>BRATTSTRÖM, L ; EL WILCKEN, D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c450t-88b4f93d8c7f0a70bc8b71328be2d033e80b41a97d8905637005b8cab2830ffa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2000</creationdate><topic>Amino acids</topic><topic>Aminoacid disorders</topic><topic>Biological and medical sciences</topic><topic>Blood and lymphatic vessels</topic><topic>Cardiology. Vascular system</topic><topic>Cardiovascular disease</topic><topic>Cardiovascular Diseases - etiology</topic><topic>Cardiovascular Diseases - prevention &amp; control</topic><topic>Dietary Supplements</topic><topic>Enzymes</topic><topic>Errors of metabolism</topic><topic>Folic Acid - administration &amp; dosage</topic><topic>Homocysteine - blood</topic><topic>Homocystinuria - complications</topic><topic>Humans</topic><topic>Hyperhomocysteinemia - physiopathology</topic><topic>Kidney - physiopathology</topic><topic>Kidney Diseases - physiopathology</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Metabolic diseases</topic><topic>Miscellaneous</topic><topic>Oxidation</topic><topic>Vitamin B</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>BRATTSTRÖM, L</creatorcontrib><creatorcontrib>EL WILCKEN, D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Physical Education Index</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>The American journal of clinical nutrition</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>BRATTSTRÖM, L</au><au>EL WILCKEN, D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Homocysteine and cardiovascular disease : cause or effect?</atitle><jtitle>The American journal of clinical nutrition</jtitle><addtitle>Am J Clin Nutr</addtitle><date>2000-08-01</date><risdate>2000</risdate><volume>72</volume><issue>2</issue><spage>315</spage><epage>323</epage><pages>315-323</pages><issn>0002-9165</issn><eissn>1938-3207</eissn><coden>AJCNAC</coden><abstract>Both markedly and mildly elevated circulating homocysteine concentrations are associated with increased risk of vascular occlusion. Here we review possible mechanisms that mediate these effects. Inborn errors of homocysteine metabolism result in markedly elevated plasma homocysteine (200-300 micromol/L) and thromboembolic (mainly venous) disease: treatment to lower but not to normalize these concentrations prevents vascular events. Mild homocysteine elevation (&gt;15 micromol/L) occurs in approximately 20-30% of patients with atherosclerotic disease. Usually, this is easily normalized with oral folate and ongoing trials are assessing the effect of folate treatment on outcomes. Although there is evidence of endothelial dysfunction with both markedly and mildly elevated homocysteine concentrations, the elevated homocysteine concentration in atherosclerotic patients is also associated with most standard vascular risk factors, and importantly, with early decline in renal function, which is common in atherosclerosis. Decline in renal function alone causes elevated plasma homocysteine (and cysteine). These observations suggest that mild hyperhomocysteinemia could often be an effect rather than a cause of atherosclerotic disease. Data on the common C677T methylenetetrahydrofolate reductase polymorphism supports this, in that, although homozygosity is a frequent cause of mild hyperhomocysteinemia when plasma folate is below median population concentrations, it appears not to increase cardiovascular risk. Indeed, there is recent evidence suggesting an acute antioxidant effect of folic acid independent of its effect on homocysteine concentrations. This antioxidant mechanism may oppose an oxidant effect of homocysteine and be relevant to treatment of patients with vascular disease, especially those with chronic renal insufficiency. Such patients have moderately elevated plasma homocysteine and greatly increased cardiovascular risk that is largely unexplained.</abstract><cop>Bethesda, MD</cop><pub>American Society for Clinical Nutrition</pub><pmid>10919920</pmid><doi>10.1093/ajcn/72.2.315</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0002-9165
ispartof The American journal of clinical nutrition, 2000-08, Vol.72 (2), p.315-323
issn 0002-9165
1938-3207
language eng
recordid cdi_proquest_miscellaneous_71244845
source MEDLINE; EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection
subjects Amino acids
Aminoacid disorders
Biological and medical sciences
Blood and lymphatic vessels
Cardiology. Vascular system
Cardiovascular disease
Cardiovascular Diseases - etiology
Cardiovascular Diseases - prevention & control
Dietary Supplements
Enzymes
Errors of metabolism
Folic Acid - administration & dosage
Homocysteine - blood
Homocystinuria - complications
Humans
Hyperhomocysteinemia - physiopathology
Kidney - physiopathology
Kidney Diseases - physiopathology
Medical research
Medical sciences
Metabolic diseases
Miscellaneous
Oxidation
Vitamin B
title Homocysteine and cardiovascular disease : cause or effect?
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-24T22%3A51%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Homocysteine%20and%20cardiovascular%20disease%20:%20cause%20or%20effect?&rft.jtitle=The%20American%20journal%20of%20clinical%20nutrition&rft.au=BRATTSTR%C3%96M,%20L&rft.date=2000-08-01&rft.volume=72&rft.issue=2&rft.spage=315&rft.epage=323&rft.pages=315-323&rft.issn=0002-9165&rft.eissn=1938-3207&rft.coden=AJCNAC&rft_id=info:doi/10.1093/ajcn/72.2.315&rft_dat=%3Cproquest_cross%3E57795187%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=231927381&rft_id=info:pmid/10919920&rfr_iscdi=true